December 22, 2020

Dear Healthcare Provider,

We are writing to share a supply-status update to the information we provided during the week of December 14, regarding the potential for near-term supply interruptions of NATPARA® (parathyroid hormone) for Injection that may impact U.S. patients receiving NATPARA through the Special Use Program.

Since that supply update, the manufacturing disruption impacting the availability of NATPARA 100-mcg and NATPARA 75-mcg has now been mitigated. This means that **we are no longer expecting near-term supply interruptions for any NATPARA dose for patients receiving NATPARA through the Special Use Program.**

If you have submitted an updated prescription form modifying the dose for a patient currently receiving NATPARA 100-mcg or NATPARA 75-mcg through the SUP, thank you for your diligence in preparing for the potential supply interruption. Since the updated prescription was only to be actioned in the event of an actual stockout of either of these strengths, your patient will continue to receive their current dosing prescription of NATPARA according to their regular shipment schedule. Revised prescriptions that were submitted in preparation for potential near-term supply interruptions will be kept on file in the event of a future supply interruption. If you would like to make any changes to your patient's current prescription, please contact OnePath® at 866-888-0660, Monday through Friday 8:30 AM – 8:00 PM ET, to be connected to the pharmacy dispensing the medication for this program.

Takeda OnePath® Patient Support Managers plan to reach out to patients receiving either NATPARA 100-mcg or NATPARA 75-mcg in the coming days to provide the update that we are no longer expecting near-term supply interruptions for NATPARA and to answer questions related to the patient's shipment schedule or the Special Use Program.

We recognize that we have been communicating about supply frequently since October 2020, and we are doing that to ensure that you and your patient have time to discuss treatment plans in the event of actual NATPARA supply interruptions. This is especially important because any potential interruption or reduction in the daily dose of NATPARA can cause severe hypocalcemia. We appreciate your patience during the past few months as we worked to maintain supply continuity.

At this time, we do not anticipate near-term supply interruptions for any NATPARA dose. However, we are closely monitoring all NATPARA doses based on the supply demands of the Special Use Program. We are committed to supply continuity and will provide another update on all NATPARA doses by March 2021.

Compliance with Special Use Program Terms & Conditions
It is important to remind SUP-enrolled patients that each NATPARA cartridge under the Special Use Program (single dose use) is intended for one use only, and that used cartridges with remaining product are to be returned to Takeda in accordance with the Special Use Program (single dose use) instructions. Non-compliance with the rules under the Special Use Program (single dose use) could result in termination of the patient's ability to receive NATPARA product through the program.

Reporting Adverse Events
Healthcare providers and patients are encouraged to report adverse events in patients taking NATPARA to Takeda at 1-800-828-2088. You are encouraged to report negative side effects of prescription drugs to the U.S. Food & Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Medical Information
You may also contact our medical information department at 1-800-828-2088 if you have any questions about the information contained in this message or the safe and effective use of NATPARA.

This communication is not intended as a complete description of the benefits and risks related to the use of NATPARA. Please visit www.natpara.com for the full Prescribing Information and Medication Guide. For additional information, please call Takeda at 1-800-828-2088 or visit www.natpara.com.

We appreciate your patience over the past few months as we worked to maintain supply continuity.

Sincerely,

Tom Koutsavlis
Head, US Medical

US-NAT-0359v1.0 12/20